Commodore Capital portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Commodore Capital reported a $1.7 bn portfolio of 33 positions to the SEC as of the end of Q2 2026. Its largest positions are RLAY, ELVN, ALKS. During the quarter it opened Tango Therapeutics and Editas Medicine and exited Erasca and Xenon Pharmaceuticals.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Commodore Capital has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Sep 30, 2026 · filed Oct 7, 2026 · filing ↗
Stake reported in the company · event of Sep 24, 2026 · filed Oct 1, 2026 · filing ↗
- 13GJatt III Acquisition5.2 %
Stake reported in the company · event of Aug 26, 2026 · filed Sep 2, 2026 · filing ↗
- 13GInflaRxIFRX5.1 %
Stake reported in the company · event of Aug 10, 2026 · filed Aug 17, 2026 · filing ↗
- 13G/AImmunicIMUX9.9 %
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
- 13G/AVistagen TherapeuticsVTGN9.9 %
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Plus 4 more, in its EDGAR filings.
What changed this quarter
26 positions with a change (4 new, 6 added to, 9 trimmed, 7 sold); also, 1 entered through an IPO, 1 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Spyre Therapeutics−56%fewer sharesReduced5.6% → 4.5%
- Relay Therapeutics−29%fewer sharesReduced9.8% → 13.4%
- Nuvalent−88%fewer sharesReduced4.9% → 0.7%
- Tango Therapeutics+4.1 ppof portfolioNew— → 4.2%
- Alkermes plc.−29%fewer sharesReduced8.6% → 9.4%
- Kymera Therapeutics−67%fewer sharesReduced3.6% → 1.7%
- Erasca−3.0 ppof portfolioSold out3.0% → —
- Celldex Therapeutics−50%fewer sharesReduced4.9% → 3.0%
- Xenon Pharmaceuticals−2.8 ppof portfolioSold out2.8% → —
- Nurix Therapeutics−2.0 ppof portfolioSold out2.0% → —
- Corvus Pharmaceuticals−1.9 ppof portfolioSold out1.9% → —
- Editas Medicine+1.7 ppof portfolioNew— → 1.7%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Relay TherapeuticsRLAY13.4%
- Enliven TherapeuticsELVN9.9%
- Alkermes plc.ALKS9.4%
- Cogent BiosciencesCOGT7.0%
- Amylyx PharmaceuticalsAMLX6.0%
- Definium TherapeuticsDFTX5.6%
- Spyre TherapeuticsSYRE4.5%
- Alto NeuroscienceANRO4.3%
- Tango TherapeuticsTNGX4.2%
- EyePointEYPT3.9%
- Tyra BiosciencesTYRA3.6%
- Damora Therapeutics3.0%
- Celldex TherapeuticsCLDX3.0%
- PharvarisPHVS2.9%
- LB PharmaceuticalsLBRX2.9%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 33
Q2 2026: 68%
Q2 2026: 25.5%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 31, 2026 (high confidence).
The data, as reported: COMMODORE CAPITAL (CRD 304370): 7.B private funds: 1 hedge (gross assets $2.4 bn); 5.D assets by client type: pooled vehicles 100% (of $2.4 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Bain Capital Life Sciences InvestorsInvestment firm · $1.7 bn
- Theleme Partners LLPInvestment firm · $1.7 bn
- AEW Capital ManagementInvestment firm · $1.7 bn
- No Street GPInvestment firm · $1.7 bn
- Dendur CapitalInvestment firm · $1.7 bn
- First Light Asset ManagementInvestment firm · $1.6 bn